SO-007

Regorafenib plus nivolumab in patients with advanced colorectal or gastric cancer: an open-label, dose-finding, and dose-expansion phase 1b trial (REGONIVO, EPOC1603)

Authors

 

HaraH 1
FukuokaS 2
TakahashiN 3
KojimaT 4
KawazoeA 5
AsayamaM 6
YoshiiT 1
KotaniD 7
TamuraH 5
MikamotoY 5
SugamaA 8
WakabayashiM 9
NomuraS 10
SatoA 10
TogashiY 2
NishikawaH 2
ShitaraK 11
Department of Gastroenterology, Saitama Cancer Center, Saitama, Japan

Division of Cancer Immunology, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center Hospital East, Kashiwa, Japan Department of Gastroenterology, Saitama Cancer Center, Kitaadachi, Japan National Cancer Center Hospital East, Kashiwa, Japan National Cancer Center Hospital East, Kashiwa-shi, Japan Saitama Cancer Center, Saitama, Japan Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan National Cancer Center, Kashiwa, Japan Clinical Research Support Office, National Cancer Center Hospital East, Kashiwa, Japan Clinical Research Support Office, National Cancer Center Hospital East, Kashiwa-city, Japan National Cancer Center, Kashiwa, Japan

 

Stay in the know.
OncNet Newsletter